Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

"This analysis suggests that, in 2005, an estimated 1,290,900 men in the United States, or about one-third of all American males, were diagnosed with prostate cancer, representing an average annual incidence rate of 62 cases per 100,000 male population. Among the estimated 1,290,900 men, about 10,800 men died from prostate cancer. This number represents a 4.5% total mortality rate for all causes of death, and approximately 2.7% of the total number of deaths among all U.S. men." - Anonymous Online Contributor

"Most advanced prostate cancers cannot be cured by conventional therapeutic modalities. However, in a minority of patients a limited number of salvage radiation therapies can result in modest tumour control. A cure is not possible in spite of these treatments. Consequently, the term 'cure' ought to be restricted to a control, particularly because of the lack of a 'complete' cure in advanced prostate cancer." - Anonymous Online Contributor

"The disease's prevalence globally in males is 6.2 per 100,000 men, and 10 percent in United States will be diagnosed and diagnosed 1 year after diagnosis. The disease usually starts out in the early 20s. The average life expectancy post diagnosis is a little more than 8 years. The typical time from onset to death is 1 year. The common presenting symptom is bladder problems. One in every four men will also have trouble urinating.\n\nThe disease is more common in Caucasians and Asians. More than half of the world's people have the disease but more than half of those diagnosed have the disease in the west." - Anonymous Online Contributor

"The genetics, environment, lifestyle, and lifestyle choices of men may in part explain how prostate cancer develops. Research is needed to identify men who are at high risk, and then to develop effective preventive measures." - Anonymous Online Contributor

"Pulsed-dose rate brachytherapy for prostate brachytherapy is now a standard treatment, typically in combination with external-beam radiotherapy, hormonal therapy, and/or salvage chemotherapy. Sipuleucel-T may be a viable treatment option for certain prostate cancer patients.\n" - Anonymous Online Contributor

"Symptoms of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) include abnormal bowel or bladder function, recurrent urinary infections, bone pain, and loss of libido. The prostate cancer diagnosis is usually made at an earlier age on signs from the prostate alone than from signs of other cancers. Symptoms of prostate cancer are often not notifiable. Patients should be advised to see a medical oncologist as soon as possible when they present with the symptoms of prostate cancer." - Anonymous Online Contributor

"Prostate cancer is a debilitating disease that deserves serious consideration and proper management. If the disease is detected early, the patient can be treated in a conservative manner avoiding complications. If there is a disease of long duration, even then, with proper treatment and follow ups, patient is less likely to go to hospital because is asymptomatic. However, careful follow up even in asymptomatic patient is still necessary to avoid complications such as urethral strictures and bladder cancer." - Anonymous Online Contributor

"In the absence of complete tumour volume coverage of surrounding normal tissues, the dosimetric parameters from the initial planning CT may be significantly different from actual treatment-delivered sbrt. Tumour shrinkage, but the lack of complete tumour coverage still may improve the efficacy of sbrt. The initial planning CT should not be the only source of information for sbrt treatment delivery. This is important considering the need for the accuracy in delivering high dose of radiation with no underdoses especially for small tumour volumes, where maximal tumour response is required." - Anonymous Online Contributor

"Because patient characteristics do not always match well among clinical trial groups, clinicians should consider these demographics when initiating clinical trials as a means to optimize patient benefit from trial participation." - Anonymous Online Contributor

"Stereotactic body radiation therapy (sbrt) is an effective treatment for [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) that is currently being used less frequently. It is a technique of high-dose, high fraction-rate, high-volume radiotherapy, which delivers a high dose to the tumor and a low dose to normal tissues and organs around the tumor. If necessary, radiosurgery may be used to treat tiny secondary cancers and their metastases that are not amenable to surgical resection or embolization. In clinical practice, the stereotactic technique achieves a cure rate close to that obtained by radical prostatectomy. It yields low rates of toxicity and maintains satisfactory urinary and erectile function." - Anonymous Online Contributor

"It is generally agreed that there are at least four main categories of risk factors that play a leading role in the risk of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer): genetic, environmental, viral, and nutritional. These factors affect the rate of development, the time delay for presentation of disease, and the stage of the disease. However, these categories are not exclusive to prostate cancer. Some cancer can result from numerous risk factors. The combination of these risk factors may also affect the aggressiveness of prostate cancer (which has been called the constellation of disease/risk factors): Genetic factors + Viral factors + Nutrition. As the incidence has grown, disease severity has increased, and mortality rates have increased along with improved early detection and treatment." - Anonymous Online Contributor

"There seems to be a strong genetic component of prostate cancer. The risk of developing prostate cancer appears to increase significantly with a family history of prostate cancer." - Anonymous Online Contributor